18 results about "Cell signaling" patented technology

Antibodies that specifically bind to TrkB and methods for using the same are described. Neuroprotective agonist antibodies are described, as indicated by their effect on enhancing the survival of retinal ganglion cells in vitro, and these agonist antibodies may be used to treat eye disorders, such as glaucoma. Additionally, other neuronal diseases or disorders, including those characterized by partial neuronal damage, benefit from treatment using these agonist antibodies. In certain embodiments, the present invention comprises antibodies that bind to TrkB and mediate cell signaling. The antibodies of the present invention may be whole human, non-natural antibodies formulated as injectable excipients.

Disclosed herein are cell signaling complexes, such as chimeric cytokine complexes, and their uses. In some embodiments, the chimeric cytokine complex comprises a protein cage polypeptide, a plurality of engineered Fc antibody domains bound to the protein cage polypeptide, and one or more cytokines linked to each of the plurality of engineered Fc antibody domains. Also disclosed are Fc-cytokine complexes and their uses. In some embodiments, the Fc-cytokine complex comprises engineered Fc antibody domains and one or more cytokines linked to the engineered Fc antibody domains.

The present invention relates to a cosmetic composition for promoting skin regeneration, and more particularly, to a cosmetic composition for promoting skin regeneration by further comprising a polydeoxyribonucleotide (PDRN) in a composition comprising a sponge microneedle, a lactic acid bacteria exosome, and a ceramide in a specific weight ratio, and more particularly, to a cosmetic composition for promoting skin regeneration by adding a polydeoxyribonucleotide (PDRN) to a composition comprising a sponge microneedle, a lactic acid bacteria exosome, and a ceramide in a specific weight ratio. The sponge microneedle forms a microchannel in a skin cuticle to promote transmission of effective components, the lactic acid bacteria exosome induces cell viability through a cell signal transduction function, and the ceramide strengthens a skin barrier. By adding PDRN in the range of 0.001 to 3% by weight relative to the total weight of the composition, proliferation of skin fibroblasts, collagen synthesis and wound healing can be promoted. The composition can be prepared into various dosage forms such as face cream, emulsion, essence, ampoules or facial masks, and the improved skin regeneration effect is provided by simultaneously achieving the effects of strengthening the skin barrier, activating cells and promoting tissue regeneration.

The present invention relates to a cosmetic composition for improving the skin condition comprising nicotinamide mononucleotide (NMN). Specifically, the present invention provides a composition comprising a sponge microneedle, a lactic acid bacteria exosome, and ceramide in a weight ratio of 0.6: 3.0: 0.01, the lactic acid bacteria exosome being obtained by culturing a Lactobacillus curvatus GFC-AM5 strain (Concentration Number: KCCM12245P) at 37 DEG C for 20 hours and then concentrating the strain by 40 times or more, and the ceramide being a mixture of the sponge microneedle, the lactic acid bacteria exosome, and the ceramide. Wherein the nicotinamide mononucleotide (NMN) is contained in an amount of 0.001 to 3% by weight relative to the total weight of the composition. The sponge microneedle promotes transmission of effective components by forming a microchannel on the skin surface, the exosome provides a cell signal transduction function, the NMN promotes cell energy metabolism by activating an NADbiosynthetic pathway in skin cells, so that cell proliferation and regeneration are enhanced, and the ceramide provides a function of strengthening a skin barrier. Accordingly, the composition of the present invention can simultaneously achieve the effects of improving skin barrier, activating cells and promoting wound healing, and can be applied to various cosmetic formulations.

A method that evaluates metastatic behavior, apoptotic behavior, and / or cancer therapy response efficiency. The method has steps. The method has steps and some of those steps are: Providing a first cell culture having cancer cells and a second cell culture. There is no physical contact between the first cell culture and the second cell culture. Co-culturing the first cell culture and the second cell culture having no physical contact therebetween under a mutual headspace. Determining concentrations of VOCs in the mutual headspace. Comparing the concentrations of the VOCs in the mutual headspace to the concentrations of VOCs in a control sample. Identifying a set of VOCs indicative of cell-to-cell signaling in cancer cells in the mutual headspace wherein the VOCs have concentrations that are significantly different as compared to the control sample. And evaluating metastatic behavior, apoptotic behavior, and / or cancer therapy response efficiency using the set of VOCs identified above.

A recombinant immune cell expresses a heterologous IgG Fc receptor. In some embodiments, the heterologous IgG Fc receptor can be a chimeric IgG Fc receptor. Generally, the chimeric IgG Fc receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain generally includes a sufficient portion of CD64 to bind to an IgG Fc region. The intracellular domain of the chimeric IgG Fc receptor includes a sufficient portion of an Fc receptor allowing immunoreceptor tyrosine-based activation motif (ITAM) to initiate cell signaling when an IgG Fc region binds to the extracellular domain.

The present invention relates to immune cells overexpressing externally introduced cell signaling pathway modulators and uses thereof. As a specific example, immune cells expressing a fusion protein comprising a chimeric antigen receptor and a cell signaling pathway modulator perform an immune response by selecting target cancer cells through the chimeric antigen receptor expressed on the cell membrane. In this case, the cell signaling pathway modulator is overexpressed in the cytoplasm, thereby being able to modulate the activity of the immune cells. Accordingly, the fusion protein comprising a chimeric antigen receptor and a cell signaling pathway modulator of the present invention, and the immune cells overexpressing the cell signaling pathway modulator can be used for the treatment of cancer.

SCGB-based preparations and methods to use these preparations to protect the glycocalyx in medical, veterinary, and cosmetic applications are provided. The secretoglobins (SCGBs) are a family of small secreted globular proteins present in all mammals and sharing conserved structure and thought to share similar immunomodulatory functions. Heparan sulfate proteoglycan proteins (HSPGs) are expressed on the outer membranes of cells and have carbohydrate side chains that, together, make up the glycocalyx. The glycocalyx is a protective layer surrounding all cells, acting as a filter regulating the passage of nutrients into the cell and modifying cell signaling by external factors. There are two major families of HSPGs including syndecans and glypicans, plus several other HSPGs in all mammals. SCGBs bind to, and interact with, HSPGs to further modulate cell signaling and cellular responses to external factors.

Disclosed herein are cell signaling complexes such as chimeric cytokine complexes and uses thereof. In some embodiments, a chimeric cytokine complex comprises a protein cage polypeptide, a plurality of engineered Fc antibody domains bound to the protein cage polypeptide, and one or more cytokines linked to each of the plurality of engineered Fc antibody domains. Also disclosed are Fc-cytokine complexes and uses thereof. In some embodiments, an Fc-cytokine complex comprises an engineered Fc antibody domain and one or more cytokines linked to the engineered Fc antibody domain.

The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.

Disclosed herein are cellular signaling complexes, such as chimeric cytokine complexes, and uses thereof. In some embodiments, a chimeric cytokine complex includes a protein cage polypeptide, a plurality of engineered Fc antibody domains bound to the protein cage polypeptide, and one or more cytokines linked to each of the plurality of engineered Fc antibody domains. Also disclosed are Fc cytokine complexes and uses thereof. In some embodiments, an Fc cytokine complex includes an engineered Fc antibody domain and one or more cytokines linked to the engineered Fc antibody domain.

The present application provides crystalline forms of 3-(5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl)-4-(methylsulfonyl) benzonitrile, pharmaceutical compositions comprising the crystalline forms and their use in the treatment of conditions associated with inhibition of PPARG cell signaling.

The present application relates to the technical field of lung adenocarcinoma ferroptosis visualization, in particular to a method for constructing a visual mouse model for real-time monitoring of lung adenocarcinoma ferroptosis process and application. The present application discloses a method for constructing a mouse model carrying exogenous Luciferase (LUC) and eGFP fragments, using live imaging technology to monitor the changes of key markers of ferroptosis in lung adenocarcinoma cells in real time, revealing the dynamic changes of cell signaling network in the process of ferroptosis, and evaluating the influence of different interventions on ferroptosis. The visual mouse model for real-time monitoring of lung adenocarcinoma ferroptosis process provided by the present application can not only deeply explore the sensitivity and resistance mechanism of lung adenocarcinoma cells to ferroptosis, provide theoretical basis and technical support for the development of new therapies based on ferroptosis, but also evaluate the influence of different drugs on ferroptosis, providing a new idea for the treatment of lung adenocarcinoma.

The present application relates to compositions comprising fusion proteins and cells expressing the proteins. The application further relates to methods of using the fusion proteins, cells, and compositions for modulating cell signaling and for selective expansion of cells. of cells. 20 26 20 47 16 18 J un 2 02 6 2 0 2 6 2 0 4 7 1 6 1 8 J u n 2 0 2 6

The present application relates to compositions comprising fusion proteins and cells expressing the proteins. The application further relates to methods of using the fusion proteins, cells, and compositions for modulating cell signaling and for selective expansion of cells. of cells. 20 26 20 47 18 18 J un 2 02 6 A B S T R A C T 2 0 2 6 2 0 4 7 1 8 1 8 J u n 2 0 2 6

A polynucleotide encoding a chimeric polypeptide comprising an amino acid sequence of a ligand capable of binding a cancer-associated receptor is provided. The amino acid sequence of the ligand being translationally fused to a heterologous amino acid sequence of a cell signaling module such that upon binding of the amino acid sequence of the ligand to the receptor, the cell signaling module is activated, wherein the ligand or cancer-associated receptor is not an immune checkpoint molecule.

The present invention is directed to methods and compositions for modulating ABCB5+ stem cell activity. The invention also relates to assays and reagents for manipulating and characterizing compounds that modulate ABCB5+ cell signaling.